Searchable abstracts of presentations at key conferences in endocrinology

ea0022p640 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Long-term treatment of Cushing's disease with pasireotide (SOM230): results from a Phase II extension study

Boscaro Marco , Zhang Yilong , Sen Kapildeb , Maldonado Mario , Schoenherr Ulrike , Findling James

Introduction: Pasireotide reduced UFC levels in 22 of 29 patients with Cushing’s disease after 15 days’ treatment (Boscaro et al. JCEM 2009). Of these 22 patients, 5 achieved normalized UFC (UFC-responders) and 17 had reduced but not normalized UFC (UFC-reducers). Results of an extension phase to this study are presented.Methods: Patients with de novo or persistent/recurrent Cushing’s disease received pasireotide 600 μg ...

ea0099p521 | Pituitary and Neuroendocrinology | ECE2024

Assessing long-term safety and efficacy of osilodrostat in prior- and new-use patients with endogenous cushing’s syndrome: a 1-year real-world interim analysis of the non-interventional, multinational LINC 6 study

Castinetti Frederic , Geer Eliza , Biller Beverly , Feelders Richard , Fleseriu Maria , Pivonello Rosario , Reincke Martin , Tabarin Antoine , Le Mouhaer Jeannie , Stermenska Julia , Maldonado Mario , Bancos Irina

Introduction: Potent 11β-hydroxylase inhibitor osilodrostat provides cortisol level control in patients with Cushing’s syndrome (CS), as demonstrated by the LINC clinical development programme in Cushing’s disease (CD) patients.1 We report data from year 1 of the prospective observational LINC6 study (NCT05382156), evaluating long-term safety and efficacy of osilodrostat in CS patients during 3 years of routine clinical practice.<p class="abstext"...